Deals Seek To Link Entresto Cost To Effectiveness
For two large insurance companies payment for the new heart failure drug Entresto will be linked to its health benefits. Both Cigna and Aetna have confirmed that they have reached a pay-for-performance deal with the drug’s manufacturer, Novartis. According to a press release issued by Cigna, “the pay-for-performance agreement ties the financial terms to how...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Larry Husten Tags: Heart Failure Policy & Ethics Prevention, Epidemiology & Outcomes Aetna Cigna Entresto Novartis Source Type: blogs
More News: Cardiology | Epidemiology | Health | Heart | Heart Failure | Insurance | Insurers | Medical Ethics